Prescription medicines with potential for foetal harm: dispensing before and during pregnancy in New Zealand, 2005–2015
- 4 April 2020
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 76 (6) , 887-896
Abstract
Purpose This study describes dispensing of potentially teratogenic prescription medicines before and during pregnancy in New Zealand over the period 2005–2015. Methods Records in a national dispensing database were linked with the members of the New Zealand Pregnancy Cohort to determine the proportion of pregnancies with at least one dispensing of a Category D or X medicine, using the Australian pregnancy risk categorisation system. Exposure was examined from 270 days prior to conception through to the end of pregnancy. Pregnancy outcomes of D/X-exposed pregnancies were reviewed. Results In the study, 874,884 pregnancies were included. Overall, Category D and X medicines were dispensed during 4.3% and 0.058% of pregnancies, respectively. After excluding misoprostol, X exposure decreased to 0.035%. Generally, dispensing declined through the 270-day pre-pregnancy period and continued to decline throughout pregnancy. Dispensing of X medicines increased over the study timeframe, whereas dispensing of D medicines increased from 2005 to 2011 then declined slightly. Smokers were more likely than non-smokers to have been dispensed a D/X medicine, and compared with European women, Māori and Pacific women were less likely to have been dispensed a D/X medicine. Excluding misoprostol, pregnancies exposed to an X medicine were more likely than D/X-unexposed pregnancies to have ended in termination. Conclusion Dispensing of potentially harmful medicines in pregnancy in New Zealand was low, particularly for Category X medicines. However, exposure did increase over the study timeframe. The inclusion of pregnancies that did not progress past early pregnancy better reflects population-level pregnancy exposure to potentially teratogenic medicines.Keywords
Funding Information
- Health Research Council of New Zealand (16/072)
This publication has 23 references indexed in Scilit:
- Use of real‐world evidence from healthcare utilization data to evaluate drug safety during pregnancyPharmacoepidemiology and Drug Safety, 2019
- Generation of a pregnancy cohort for medicine utilisation and medicine safety studies in New ZealandPharmacoepidemiology and Drug Safety, 2018
- Classifying drugs in pregnancyAustralian Prescriber, 2014
- Evolving knowledge of the teratogenicity of medications in human pregnancyAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2011
- Patterns of pregnancy exposure to prescription FDA C, D and X drugs in a Canadian populationJournal of Perinatology, 2008
- An Introduction to Categorical Data Analysis2006
- Use of prescription medications with a potential for fetal harm among pregnant womenPharmacoepidemiology and Drug Safety, 2006
- Teratogenicity of recently introduced medications in human pregnancyObstetrics & Gynecology, 2002
- Review of pregnancy labeling of prescription drugs: Is the current system adequate to inform of risks?American Journal of Obstetrics and Gynecology, 2002
- FDA classification of drugs for teratogenic risk: Teratology society public affairs committeeTeratology, 1994